CHE

Analyst Note: CHE (Chemed Corporation)

Date: 2026-06-13 Subject: Structural Setup and Business Fundamentals Review

1. Structural Readiness

State: Context-Only Conservative Entry: — Current Price: $436.27 Extension: — ATR at Breakout: — ATR Current: 3.0% (Productive) Pivot Strength: —

Setup Classification: FORMING

2. Thesis Layer

Thesis Status: TACTICAL / SETUP-LED There is no named secular thesis attached to CHE as of this date. The investment case is not driven by a macro narrative or a specific industry-wide secular trend identified in the current evidence base. Consequently, the conviction must be derived strictly from the quality of the technical setup (the forming coil) and the underlying business fundamentals. No external macro thesis should be invented to support the position; the judgment rests on the company's execution and the structural price action.

3. Business Overview

Company Profile: Chemed Corporation operates as a dual-segment service company in the Healthcare and Home Services sectors.

• VITAS (Hospice): Provides end-of-life and supportive care (hospice and palliative services) to terminally ill patients. The business model relies on a network of medical professionals (physicians, nurses, aides) and volunteers.
• Roto-Rooter (Home Services): Provides plumbing, drain cleaning, excavation, water restoration, and related property maintenance solutions to residential and commercial clients through a mix of corporate-owned locations, independent contractors, and franchised operations.

Operational Evidence (as of 2026-06-13):

• Revenue Growth & Guidance: In the Q1 2026 earnings transcript (2026-04-24), management updated full-year 2026 ADC (Average Daily Census) growth guidance to 4.5% to 5.5%, an upgrade from the original 3.5% to 4%. Revenue growth, excluding the impact of the Medicare Cap, was revised to 6.5% to 7.5%, up from the original 5.5% to 6.5%.
• Acquisition Impact: Two recent acquisitions are anticipated to contribute between $5 million and $5.5 million of revenue for the remainder of 2026.
• Segment Performance:
• VITAS: Admissions totaled 19,394 in the quarter, a 6.9% improvement year-over-year. Revenue growth was driven by a 2.2% increase in days-of-care and a 2.6% increase in the geographically weighted average Medicare reimbursement rate. Notably, no Medicare Cap billing limitation was recorded in Q1 2026, and none is anticipated for the fiscal year.
• Roto-Rooter: The segment faced headwinds, with service revenues declining 0.9% for the quarter. This was driven by a 1.9% decrease in commercial revenue and a 1.5% decrease in residential revenue. However, for the first time since Q4 2022, both residential plumbing and residential sewer/drain revenue increased during the quarter.
• Regulatory Environment: Over 90% of VITAS revenue is derived from the U.S. government via Medicare. The Medicare Cap for the period ending September 30, 2026, is set at $35,361.44 per admission, adjusted annually for inflation (the 2026 inflationary increase was 2.6%).
• Capital Structure: On April 10, 2026, the company replaced its prior credit agreement with a sixth amended and restated agreement, establishing a $450.0 million revolving credit facility (including $100.0 million for letters of credit).

4. Archetype and Conviction

Archetype: Quality Compounder CHE fits the "Quality Compounder" archetype. The business demonstrates a history of consistent growth, strong management execution (evidenced by the upward revision of guidance), and a dominant market position in its respective niches (VITAS is one of the nation's largest hospice providers; Roto-Rooter is a leader in home services).

Conviction Stack:

• Thesis Strength: Low (Tactical only; no macro thesis).
• Evidence Quality: High. The evidence base is robust, featuring specific guidance upgrades, clear segment performance metrics, and transparent regulatory data.
• Structural Quality: Moderate to High. The company has a strong balance sheet ($450M revolver) and is navigating regulatory headwinds (Medicare Cap) effectively, with no cap limitations recorded in Q1 2026.
• Valuation Context: Forward consensus EPS for FY1 is $24.35, and FY2 is $26.91. The current price of $436.27 implies a forward P/E of approximately 17.9x for FY1, which is reasonable for a compounder with double-digit growth expectations, though the Roto-Rooter decline introduces a slight drag on the multiple expansion potential.

Rerating Potential: The rerating potential is tied to the successful integration of acquisitions and the sustained recovery of Roto-Rooter's commercial and residential revenue streams. If VITAS continues to outperform the high end of expectations (as noted in Q1) and Roto-Rooter stabilizes, the "Quality Compounder" narrative could drive a re-rating.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Roto-Rooter Turnaround: Sustained sequential growth in Roto-Rooter's commercial and residential revenue, reversing the current 1.9% and 1.5% declines.
• Guidance Reiteration: Management reaffirming or further upgrading the 2026 ADC and revenue growth ranges in subsequent quarters.

What Would Invalidate the Case:

• Regulatory Shock: The imposition of the Medicare Cap billing limitation in a subsequent quarter, which would materially impact VITAS revenue given that >90% of its revenue is Medicare-based.
• Operational Deterioration: A significant decline in VITAS admissions or days-of-care, or a failure to integrate the $5M-$5.5M acquisition revenue.

Evidence Gaps:

• No named secular thesis: The lack of a macro narrative means the setup is purely tactical.
• Roto-Rooter Specifics: While the decline is noted, the specific drivers for the commercial vs. residential split in the broader market context are not fully detailed beyond the revenue percentages.
• Long-term Cap Exposure: While Q1 2026 had no cap issues, the long-term impact of the $35,361.44 cap on future growth rates beyond 2026 is not explicitly modeled in the current evidence.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Management upgraded full-year ADC growth guidance to 4.5-5.5% and revenue growth to 6.5-7.5%; VITAS admissions grew 6.9% with no Medicare Cap limitations recorded in Q1 2026; Forward consensus EPS for FY1 is $24.35. Key risks: Roto-Rooter revenue declined 0.9% driven by commercial and residential drops; Over 90% of VITAS revenue is from Medicare, creating regulatory concentration risk; Technical setup is still forming and has not yet broken out. Expected path: Management expects continued growth from acquisitions and Medicare reimbursement rate increases; structural implication is a potential re-rating if Roto-Rooter stabilizes and VITAS maintains momentum. Expected horizon: 3 to 6 months for the setup to resolve into a confirmed breakout or invalidation.